Recent Advances with Liposomes as Drug Carriers - Advanced Biomaterials and Biodevices - page 109

127. Randles, E.G. and P.R. Bergethon, A photodependent switch of liposome sta-
bility and permeability. Langmuir , 2013. 29(5): p. 1490-7.
128. Wu, G., et al. , Remotely triggered liposome release by near-infrared light
absorption via hollow gold nanoshells. Journal of the American Chemical
Societ y, 2008. 130(26): p. 8175-7.
129. Nobs, L., et al. , Current methods for attaching targeting ligands to liposomes
and nanoparticles. J Pharm Sci , 2004. 93(8): p. 1980-1992.
130. Torchilin, V., et al. , p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and
simple attachment of specii c ligands, including monoclonal antibodies, to
distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochimica et
Biophysica Acta (BBA)-Biomembranes , 2001. 1511(2): p. 397-411.
131. Oliveira, S., et al. , Downregulation of EGFR by a novel multivalent nano-
body-liposome platform. J Control Release , 2010. 145(2): p. 165-75.
132. Chiu, G.N., et al. , Modulation of cancer cell survival pathways using mul-
tivalent liposomal therapeutic antibody constructs. Mol Cancer h er , 2007.
6(3): p. 844-55.
133. Hertlein, E., et al. , Milatuzumab immunoliposomes induce cell death in CLL
by promoting accumulation of CD74 on the surface of B cells. Blood , 2010.
116(14): p. 2554-8.
134. Etzerodt, A., et al. , Ei cient intracellular drug-targeting of macrophages
using stealth liposomes directed to the hemoglobin scavenger receptor
CD163. J Control Release , 2012. 160(1): p. 72-80.
135. Noble, C.O., et al. , Characterization of highly stable liposomal and immu-
noliposomal formulations of vincristine and vinblastine. Cancer Chemother
Pharmacol , 2009. 64(4): p. 741-51.
136. O'Donnell, R.T., et al. , Development and characterization of CD22-targeted
pegylated-liposomal doxorubicin (IL-PLD). Invest New Drugs , 2010. 28(3):
p. 260-7.
137. Sawant, R.M., et al. , Prostate cancer-specii c monoclonal antibody 5D4 sig-
nii cantly enhances the cytotoxicity of doxorubicin-loaded liposomes against
target cells in vitro. J Drug Target , 2008. 16(7): p. 601-4.
138. Elbayoumi, T.A. and V.P. Torchilin, Tumor-specii c antibody-mediated tar-
geted delivery of Doxil reduces the manifestation of auricular erythema side
ef ect in mice. Int J Pharm , 2008. 357(1-2): p. 272-9.
139. ElBayoumi, T.A. and V.P. Torchilin, Tumor-targeted Nanomedicine s:
enhanced antitumor ei cacy in vivo of doxorubicin-loaded, long-circulating
liposomes modii ed with cancer-specii c monoclonal antibody. Clin Cancer
Res , 2009. 15(6): p. 1973-80.
140. Gupta, B. and V.P. Torchilin, Monoclonal antibody 2C5-modii ed doxoru-
bicin-loaded liposomes with signii cantly enhanced therapeutic activity
against intracranial human brain U-87 MG tumor xenograt s in nude mice.
Cancer Immunol Immunother , 2007. 56(8): p. 1215-23.
141. Elbayoumi, T.A., et al. , Antinucleosome antibody-modii ed liposomes and
lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic
agents. J Liposome Res , 2007. 17(1): p. 1-14.